Walker Peter A, Aroom Kevin R, Jimenez Fernando, Shah Shinil K, Harting Matthew T, Gill Brijesh S, Cox Charles S
Department of Surgery, University of Texas Medical School at Houston, Houston, TX 77030, USA.
Stem Cell Rev Rep. 2009 Sep;5(3):283-300. doi: 10.1007/s12015-009-9081-1. Epub 2009 Jul 31.
Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. Current clinical therapy is focused on optimization of the acute/subacute intracerebral milieu, minimizing continued cell death, and subsequent intense rehabilitation to ameliorate the prolonged physical, cognitive, and psychosocial deficits that result from TBI. Adult progenitor (stem) cell therapies have shown promise in pre-clinical studies and remain a focus of intense scientific investigation. One of the fundamental challenges to successful translation of the large body of pre-clinical work is the delivery of progenitor cells to the target location/organ. Classically used vehicles such as intravenous and intra arterial infusion have shown low engraftment rates and risk of distal emboli. Novel delivery methods such as nanofiber scaffold implantation could provide the structural and nutritive support required for progenitor cell proliferation, engraftment, and differentiation. The focus of this review is to explore the current state of the art as it relates to current and novel progenitor cell delivery methods.
创伤性脑损伤（TBI）是美国发病和死亡的主要原因。目前的临床治疗重点在于优化急性/亚急性脑内环境，尽量减少持续的细胞死亡，以及随后进行强化康复治疗，以改善TBI导致的长期身体、认知和心理社会缺陷。成体祖细胞（干细胞）疗法在临床前研究中已显示出前景，仍然是深入科学研究的重点。将大量临床前研究成功转化面临的一个基本挑战是将祖细胞输送到目标位置/器官。传统使用的载体，如静脉内和动脉内输注，已显示出低植入率和远端栓子风险。新型递送方法，如纳米纤维支架植入，可以为祖细胞增殖、植入和分化提供所需的结构和营养支持。本综述的重点是探讨与当前和新型祖细胞递送方法相关的当前技术水平。
